|Ms. Emma Walmsley||CEO & Director||N/A||N/A||47|
|Mr. Simon P. Dingemans||Chief Financial Officer and Exec. Director||2.65M||390.66k||53|
|Dr. Patrick J. T. Vallance||Pres of R&D and Exec. Director||N/A||N/A||56|
|Dr. Hal V. Barron||Chief Scientific Officer, Pres of R&D and Director||N/A||N/A||54|
|Ms. Karenann K. Terrell||Chief Digital & Technology Officer||N/A||N/A||55|
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc has a strategic drug discovery collaboration with Exscientia Limited to discover novel and selective small molecules for up to 10 disease-related targets across various therapeutic areas; and a collaboration agreement with Oklahoma Medical Research Foundation for the discovery, development, and commercialization of therapies to prevent organ damage and death caused by acute pancreatitis, lung injury, and trauma conditions. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline plc’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 1; Compensation: 1.